The Original I.P. will continue to own Key West Hand Print Fabrics' fine art library, which can be used for future ...
Scott Michael Rajeski, the CHIEF EXECUTIVE OFFICER of $SWIM ($SWIM), sold 6,119 shares of the company on 12-11-2024. We received data on the trade from a recent SEC ...
(Bloomberg) -- Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, ...
Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug addiction, making it the first major ...
With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following anoth ...
ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market. It'll take a while for the economic implications of the data to play out.
(Bloomberg) — Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound. The company ...
Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already delivered ...
BRISTOL, Wis. — Eli Lilly has announced a $3 billion expansion in Kenosha County to its manufacturing facility acquired earlier this year in Pleasant Prairie. The acquisition, expansion ...
Eli Lilly will spend $3 billion to expand a manufacturing facility in Wisconsin it bought in April, adding new capabilities to produce injectable medicines like its fast-selling weight loss and ...
Copyright 2024 The Associated Press. All Rights Reserved. David Ricks, chair and CEO of Eli Lilly, fields a question during an announcement of the company’s $3 ...